A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease
- 1 January 1987
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 92 (1) , 48-53
- https://doi.org/10.1016/0016-5085(87)90838-9
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effectDigestive Diseases and Sciences, 1985
- Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison SyndromeGastroenterology, 1985
- Famotidine, a new H2-receptor antagonistDigestive Diseases and Sciences, 1985
- Cimetidine, Cigarette Smoking, and Recurrence of Duodenal UlcerNew England Journal of Medicine, 1984
- Comparative effects of famotidine and cimetidine on antipyrine kinetics in healthy volunteers [letter]Published by Wiley ,1984
- 24 HOUR INTRAGASTRIC ACIDITY AND SINGLE NIGHT-TIME DOSE OF THREE H2-BLOCKERSThe Lancet, 1983
- Kinetics of antisecretory action of a new H2-antagonist, YM-11170, in conscious dogsEuropean Journal of Pharmacology, 1983
- Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortexNature, 1983
- Effect of a new potent H2-receptor antagonist 3[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea pigBiochemical Pharmacology, 1983
- SMOKING IMPAIRS THERAPEUTIC GASTRIC INHIBITIONThe Lancet, 1983